AtriCure Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
AtriCure Inc. (ATRC) PT Raised to $30 at Northland Capital Markets
August 2, 2018 1:30 PM EDTNorthland Capital Markets raised its price target on AtriCure Inc. (NASDAQ: ATRC) to $30.00 (from $25.00) while maintaining an Outperform rating.
Analyst Suraj Kalia commented, "Atricure' Q2-18 revenues of $51.8M were roughly in-line with our estimate @ $50.8M. Appendage mgmt continues to be... More
AtriCure Inc. (ATRC) PT Raised to $36 at Needham & Company
August 2, 2018 6:31 AM EDTNeedham & Company raised its price target on AtriCure Inc. (NASDAQ: ATRC) to $36.00 (from $32.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "ATRC's 2Q18 revenue accelerated to 13.5% vs. 12.0% in 1Q18 and beat consensus. Management raised its 2018 revenue guidance to $193-197M... More
AtriCure (ATRC) Tops Q2 EPS by 22c
August 1, 2018 4:38 PM EDTAtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.01), $0.22 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $51.8 million versus the consensus estimate of $49.9 million.
GUIDANCE:
AtriCure sees FY2018 revenue of $193-197 million, versus the consensus of $195... More
